WallStreetZenWallStreetZen

NASDAQ: CRNX
Crinetics Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CRNX

Based on 5 analysts offering 12 month price targets for Crinetics Pharmaceuticals Inc

Min Forecast
$55.00+80.8%
Avg Forecast
$72.20+137.34%
Max Forecast
$91.00+199.15%

Should I buy or sell CRNX stock?

Based on 5 analysts offering ratings for Crinetics Pharmaceuticals Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CRNX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CRNX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their CRNX stock forecasts and price targets.

CRNX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-25
lockedlocked$00.00+00.00%2025-02-28
lockedlocked$00.00+00.00%2025-01-22
lockedlocked$00.00+00.00%2025-01-13
lockedlocked$00.00+00.00%2024-11-14

1 of 1

Forecast return on equity

Is CRNX forecast to generate an efficient return?

Company
0.59%
Industry
147.71%
Market
81.76%
CRNX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRNX forecast to generate an efficient return on assets?

Company
0.54%
Industry
35.52%
CRNX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRNX earnings per share forecast

What is CRNX's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$4.33
Avg 2 year Forecast
-$4.75
Avg 3 year Forecast
-$3.13

CRNX revenue forecast

What is CRNX's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$5.6M+441.77%
Avg 2 year Forecast
$46.5M+4,376.03%
Avg 3 year Forecast
$224.2M+21,477.09%
CRNX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRNX revenue growth forecast

How is CRNX forecast to perform vs Biotechnology companies and vs the US market?

Company
468.62%
Industry
65.42%
Market
10.4%
CRNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRNX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRNX$30.42$72.20+137.34%Strong Buy
PTGX$46.28$69.33+49.81%Strong Buy
SWTX$37.92$73.50+93.83%Strong Buy
SRRK$30.75$47.33+53.93%Strong Buy
CPRX$22.52$33.20+47.42%Strong Buy
View Top Biotech Stocks

Crinetics Pharmaceuticals Stock Forecast FAQ

Is Crinetics Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: CRNX) stock is to Strong Buy CRNX stock.

Out of 5 analysts, 3 (60%) are recommending CRNX as a Strong Buy, 2 (40%) are recommending CRNX as a Buy, 0 (0%) are recommending CRNX as a Hold, 0 (0%) are recommending CRNX as a Sell, and 0 (0%) are recommending CRNX as a Strong Sell.

If you're new to stock investing, here's how to buy Crinetics Pharmaceuticals stock.

What is CRNX's earnings growth forecast for 2025-2027?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.

Crinetics Pharmaceuticals's earnings in 2025 is -$298,408,000.On average, 10 Wall Street analysts forecast CRNX's earnings for 2025 to be -$402,434,927, with the lowest CRNX earnings forecast at -$474,547,544, and the highest CRNX earnings forecast at -$305,199,205. On average, 9 Wall Street analysts forecast CRNX's earnings for 2026 to be -$442,389,969, with the lowest CRNX earnings forecast at -$574,109,479, and the highest CRNX earnings forecast at -$235,412,801.

In 2027, CRNX is forecast to generate -$291,241,924 in earnings, with the lowest earnings forecast at -$492,226,766 and the highest earnings forecast at -$70,716,889.

What is CRNX's revenue growth forecast for 2025-2027?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 468.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Crinetics Pharmaceuticals's revenue in 2025 is $1,039,000.On average, 8 Wall Street analysts forecast CRNX's revenue for 2025 to be $523,770,220, with the lowest CRNX revenue forecast at $130,267,953, and the highest CRNX revenue forecast at $1,850,549,324. On average, 8 Wall Street analysts forecast CRNX's revenue for 2026 to be $4,327,315,308, with the lowest CRNX revenue forecast at $2,336,448,789, and the highest CRNX revenue forecast at $11,009,782,162.

In 2027, CRNX is forecast to generate $20,860,179,540 in revenue, with the lowest revenue forecast at $11,691,548,800 and the highest revenue forecast at $30,006,292,534.

What is CRNX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CRNX) forecast ROA is 0.54%, which is lower than the forecast US Biotechnology industry average of 35.52%.

What is CRNX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year CRNX price target, the average CRNX price target is $72.20, with the highest CRNX stock price forecast at $91.00 and the lowest CRNX stock price forecast at $55.00.

On average, Wall Street analysts predict that Crinetics Pharmaceuticals's share price could reach $72.20 by Mar 25, 2026. The average Crinetics Pharmaceuticals stock price prediction forecasts a potential upside of 137.34% from the current CRNX share price of $30.42.

What is CRNX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's current Earnings Per Share (EPS) is -$3.69. On average, analysts forecast that CRNX's EPS will be -$4.33 for 2025, with the lowest EPS forecast at -$5.10, and the highest EPS forecast at -$3.28. On average, analysts forecast that CRNX's EPS will be -$4.75 for 2026, with the lowest EPS forecast at -$6.17, and the highest EPS forecast at -$2.53. In 2027, CRNX's EPS is forecast to hit -$3.13 (min: -$5.29, max: -$0.76).

What is CRNX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CRNX) forecast ROE is 0.59%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.